Philips' Brilliance iCT boosts quality with new technology
Volume-rendered image processed from data acquired using the Philips 256-slice Brilliance iCT scanner at WellStar Kennestone Hospital in Marietta, GA, shows right iliac artery stenosis and multiple calcifications on left iliac artery. Bony landmarks are ghosted in background, the result of a new visualization technique introduced by Philips to assist in planning interventions. The Marietta installation boosts the number of Philips 256-slice CTs to nine. These sites, located at medical facilities around the world, have scanned more than 6000 patients, according to Philips Healthcare. With rotational speeds up to 0.27 seconds and a detector that spans 8 cm, the iCT supports applications in trauma, cardiac, interventional, pediatric, vascular, and bariatrics, as well as general imaging. Slotted anode and dual-support spiral groove bearing built into the scanner's x-ray tube enable 120- kW imaging and focal spot integrity at high rotational speeds. 'Smart' focal spot simultaneously deflects x-ray beam in x- and z-axes to acquire double the data during each rotation. (Provided by Philips)
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
